LAKESHORE BIOPHARMA CO., LTD |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.02 USD | +12.45% |
|
+4.31% | +99.61% |
| May. 24 | YS Biopharma to Become LakeShore Biopharma, Ticker Symbol to Change to LSB From YS Starting May 28 | MT |
| May. 21 | YS Biopharma Co., Ltd. Approves Board Appointments | CI |
| Sales 2024 * | 596M 82.31M | Sales 2025 * | 827M 114M | Capitalization | 1.39B 192M |
|---|---|---|---|---|---|
| Net income 2024 * | -297M -41M | Net income 2025 * | -122M -16.84M | EV / Sales 2024 * | 2.33 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.68 x |
| P/E ratio 2024 * |
-2.32
x | P/E ratio 2025 * |
-6.78
x | Employees | 773 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 18.57% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +12.45% | ||
| 1 week | +4.31% | ||
| Current month | +44.89% | ||
| 1 month | +27.50% | ||
| 3 months | +163.57% | ||
| 6 months | +63.51% | ||
| Current year | +99.61% |
1 week
0.88
1.10
1 month
0.701.10
Current year
0.351.10
1 year
0.351.78
3 years
0.3512.93
5 years
0.3512.93
10 years
0.3512.93
| Managers | Title | Age | Since |
|---|---|---|---|
Hui Shao
CEO | Chief Executive Officer | 55 | 20-12-30 |
Chun Yuan Wu
DFI | Director of Finance/CFO | 46 | 20-12-30 |
Zenaida Mojares
CTO | Chief Tech/Sci/R&D Officer | 65 | 21-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Viren Mehta
BRD | Director/Board Member | 74 | - |
Hui Shao
CEO | Chief Executive Officer | 55 | 20-12-30 |
Ajit Shetty
CHM | Chairman | 77 | 20-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-24 | 1.02 | +12.45% | 107,250 |
| 24-05-23 | 0.9071 | -1.28% | 32,797 |
| 24-05-22 | 0.9189 | -6.23% | 37,682 |
| 24-05-21 | 0.98 | +2.08% | 64,000 |
| 24-05-20 | 0.96 | -1.83% | 51,169 |
Delayed Quote Nasdaq, May 24, 2024 at 04:30 pm EDT
More quotes
YS Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. The Company's vaccine product YSJATM rabies vaccine has been commercialized. The Company also has four product candidates under various clinical development stages, including PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, PIKA YS-ON-001 and PIKA YS-HBV-001, and four preclinical stage product candidates, targeting HBV, influenza and cancer with enormous medical demand. In addition, the Company is working on a series of therapeutic targets, rabies and products at the discovery stage.
Sector
Pharmaceuticals
Calendar
2024-08-12
- Q1 2025 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
7.387
CNY
Average target price
29.98
CNY
Spread / Average Target
+305.86%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +99.61% | 192M | |
| -2.10% | 90.02B | |
| -1.18% | 39.15B | |
| -15.83% | 31.71B | |
| +62.74% | 26.47B | |
| -21.68% | 14.34B | |
| -8.73% | 12.89B | |
| -15.05% | 11.18B | |
| -45.69% | 10.97B | |
| +3.75% | 8.94B |
- Stock Market
- Equities
- YS Stock
